- Ixico said it had signed a new contract with an existing global pharmaceutical customer valued at $2.7m over a seven year term.

Ixico would provide its technology enabled imaging services in a clinical trial of a novel therapeutic to treat people with progressive supranuclear palsy, a rare neurodegenerative disease.

At 1:51pm: [LON:IXI] IXICO plc share price was +3.5p at 37.5p

Story provided by